{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:43Z","timestamp":1792601443756,"version":"4.5.0"},"reference-count":61,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900794"],"award-info":[{"award-number":["81900794"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Cardiovascular Disease"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Psychotropic medications extend corrected QT (QTc) period in the electrocardiogram (ECG). Psychiatric patients exposed to \u2a7e1 psychotropic medication(s) represent a group with marked probability of drug-activated QTc-prolongation. Prolonged QTc interval in elderly patients (age\u2009&gt;\u200960 years) is connected to greater risk of all-cause and coronary heart disease deaths. This study aimed at investigating pattern of utilization of QTc-interval protracting medications, QT-extending drug interactions, and prevalence of QTc-interval extending hazard factors in elderly patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> This was a cross-sectional, prospective study at the Psychiatry OPD at All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India from 1 October 2017 to 30 August 2019 employing the pertinent prescriptions. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> A total of 832 elderly patients (age 60 years or more) visiting the Psychiatry OPD during the aforementioned study duration were investigated. About 420 (50.5%) patients were males while 412 (49.5%) were females. Of the 832 patients, 588 (70.7%) were using interacting agents with capacity to produce TdP. Almost 1152 interacting torsadogenic medication pairs were unraveled. As per AzCERT\/CredibleMeds Classification, 1016 (48.8%), 724 (34.8%), and 248 (12%) agents with potential to interact were identified with \u2018known\u2019, \u2018possible\u2019, and \u2018conditional risk of TdP\u2019, respectively. The common interacting medications belonged to antidepressant (288), proton pump inhibitor (364), antipsychotic (340), antinausea (184), antimicrobial (156), and H<jats:sub>2<\/jats:sub> receptor antagonist (60) therapeutic categories. The all-inclusive frequency of potentially inappropriate psychotropic (PIP) agents administered was 62% (1343\/2166) with Beers Criteria 2019, and 46% (997\/2166) with STOPP Criteria 2015. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> Many geriatric patients were administered drugs and drug combinations with heightened proclivity toward QT-interval prolongation. Furthermore, reliable evidence-based online drug knowledge resources, such as AzCERT\/CredibleMeds Drug Lists, Medscape Drug Interactions Checker, Epocrates Online Interaction Check, and Drugs.com Drug Interactions Checker, can facilitate clinical professionals in selecting drugs for psychiatric patients. A wise choice of medications is imperative to preclude serious adverse sequelae. Therefore, we need to exigently embrace precautionary safety means, be vigilant, and forestall QT-extension and TdP in clinical environments. <\/jats:p><\/jats:sec>","DOI":"10.1177\/17539447211058892","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T12:54:30Z","timestamp":1638190470000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["Leading 20 drug\u2013drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3222-2527","authenticated-orcid":false,"given":"Biswadeep","family":"Das","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Virbhadra Road, Rishikesh 249 203, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saravana Kumar","family":"Ramasubbu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Rishikesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Agnihotri","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Rishikesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barun","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Rishikesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram Singh","family":"Rawat","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Rishikesh, Rishikesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"bibr1-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000129322.97266.F3"},{"key":"bibr2-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2007.06.023"},{"key":"bibr3-17539447211058892","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-12-199312150-00006"},{"key":"bibr4-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00477-3"},{"key":"bibr5-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03660.x"},{"key":"bibr6-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2013.11.009"},{"key":"bibr7-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.001"},{"key":"bibr8-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032426"},{"key":"bibr9-17539447211058892","unstructured":"U.S. Department of Health and Human Services. Guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, https:\/\/www.fda.gov\/media\/71372\/download (accessed October 2005)."},{"key":"bibr10-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.71.1.17"},{"key":"bibr11-17539447211058892","unstructured":"Woosley RL, Heise CW, Gallo T, et al. QTdrugs List, www.CredibleMeds.org (accessed 23 July 2020)."},{"key":"bibr12-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(91)91315-6"},{"key":"bibr13-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1097\/00045415-200008020-00008"},{"key":"bibr14-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(83)80226-5"},{"key":"bibr15-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/1.2.65"},{"key":"bibr16-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15767"},{"key":"bibr17-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2446-0"},{"key":"bibr18-17539447211058892","first-page":"213","volume":"144","author":"O\u2019Mahony D","year":"2015","journal-title":"Age Ageing"},{"key":"bibr19-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.03.008"},{"key":"bibr20-17539447211058892","unstructured":"WHO collaborating centre for drug statistics methodology. ATC\/DDD Index 2017, https:\/\/www.whocc.no\/atc_ddd_index\/ (accessed 23 July 2020)."},{"key":"bibr21-17539447211058892","unstructured":"Medscape drug interaction checker, https:\/\/reference.medscape.com\/drug-interactionchecker (accessed 23 July 2020)."},{"key":"bibr22-17539447211058892","unstructured":"Epocrates online interaction check, https:\/\/online.epocrates.com\/interaction-check (accessed 23 July 2020)."},{"key":"bibr23-17539447211058892","unstructured":"Drugs.Com drug interactions checker, https:\/\/www.drugs.com\/drug_interactions.html (accessed 23 July 2020)."},{"key":"bibr24-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2381-5"},{"key":"bibr25-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1177\/1715163516641136"},{"key":"bibr26-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.2008.01085.x"},{"key":"bibr27-17539447211058892","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-106-5-712"},{"key":"bibr28-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9592.2001.01575.x"},{"key":"bibr29-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034282"},{"key":"bibr30-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.07.005"},{"key":"bibr31-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2008.11.011"},{"key":"bibr32-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2251"},{"key":"bibr33-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050329"},{"key":"bibr34-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12969"},{"key":"bibr35-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurger.2016.11.012"},{"key":"bibr36-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-014-9953-6"},{"key":"bibr37-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01455-9"},{"key":"bibr38-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0532-5"},{"key":"bibr39-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2018.07.002"},{"key":"bibr40-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806994"},{"key":"bibr41-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2019.1615446"},{"key":"bibr42-17539447211058892","doi-asserted-by":"publisher","DOI":"10.14503\/THIJ-16-6040"},{"key":"bibr43-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw591"},{"key":"bibr44-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(00)90126-3"},{"key":"bibr45-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2016"},{"key":"bibr46-17539447211058892","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2019.05.128"},{"key":"bibr47-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13897"},{"key":"bibr48-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2012.11.001"},{"key":"bibr49-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.150"},{"key":"bibr50-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut214"},{"key":"bibr51-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000758"},{"key":"bibr52-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000450319.21859.6d"},{"key":"bibr53-17539447211058892","unstructured":"Leiberman JA, Merrill D, Parameswarain S, et al. APA guidance on the use of antipsychotic drugs and cardiac sudden death, https:\/\/omh.ny.gov\/omhweb\/advisories\/adult_antipsychotic_use_attachement.html (accessed 23 July 2020)."},{"key":"bibr54-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12989"},{"key":"bibr55-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1017\/ipm.2013.30"},{"key":"bibr56-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0594.2012.00951.x"},{"key":"bibr57-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000701"},{"key":"bibr58-17539447211058892","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118010-00004"},{"key":"bibr59-17539447211058892","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.050088"},{"key":"bibr60-17539447211058892","volume-title":"et al. Consensus statement on high-dose antipsychotic medication","author":"Barnes T","year":"2005"},{"key":"bibr61-17539447211058892","first-page":"552","volume":"28","author":"Ames D","year":"2002","journal-title":"Encephale"}],"container-title":["Therapeutic Advances in Cardiovascular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447211058892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17539447211058892","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447211058892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:14:43Z","timestamp":1738041283000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17539447211058892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":61,"alternative-id":["10.1177\/17539447211058892"],"URL":"https:\/\/doi.org\/10.1177\/17539447211058892","relation":{},"ISSN":["1753-9447","1753-9455"],"issn-type":[{"value":"1753-9447","type":"print"},{"value":"1753-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"17539447211058892"}}